Iterum Therapeutics Extends Milestone Payment Terms with Pfizer

The latest update is out from Iterum Therapeutics ( (ITRM) ).

On May 19, 2025, Iterum Therapeutics announced that Pfizer agreed to extend the payment term for a $20 million regulatory milestone payment related to the FDA approval of ORLYNVAH™, a novel oral antibiotic for uncomplicated urinary tract infections, until October 25, 2029. This extension allows Iterum to strategically invest capital from ORLYNVAH™ sales into its launch and expansion efforts, while agreeing to increased interest rates and specific financial conditions with Pfizer.

The most recent analyst rating on (ITRM) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.

Spark’s Take on ITRM Stock

According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.

Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.

To see Spark’s full report on ITRM stock, click here.

More about Iterum Therapeutics

Iterum Therapeutics is a pharmaceutical company focused on developing next-generation oral and IV antibiotics to combat infections caused by multi-drug resistant pathogens in both community and hospital settings. Their primary product, sulopenem, is a novel penem anti-infective compound available in oral and IV formulations, targeting serious and life-threatening infections.

Average Trading Volume: 413,694

Technical Sentiment Signal: Sell

Current Market Cap: $39.44M

See more insights into ITRM stock on TipRanks’ Stock Analysis page.